|
|
| |
| Biography |
| |
Viresh Rawal received his B.S. degree from The University of Connecticut (1980) and his Ph.D. from University of Pennsylvania (1986). His doctoral research, carried out under professor Michael P. Cava, dealt with the development of an efficient route for the synthesis of the potent antitumor agent CC-1065. From 1986 to 1988 he was a postdoctoral associate at Columbia University in the laboratories of Professor Gilbert Stork. In 1988 he accepted a faculty position at The Ohio State University and was promoted to Associate Professor in 1994. In the autumn of 1995 he moved to the University of Chicago as an Associate Professor and was subsequently promoted to Professor.
His research interests are in the general area of organic synthesis, with the goal of developing effective methods and strategies for the synthesis of complex bioactive molecules. This effort has culminated in the synthesis of several intricate targets, including isocomene and (-)-isocomene, endo-hirsutene, modhephene, silphiperfol-6-ene, a-elemene, (±) and (+)-tabersonine, (+)-11-methoxytabersonine (+)-aspidospermidine, (-)-dehydroquebrachamine, (-)-quebrachamine, geissoschizal, dehydrotubifoline, akuammicine, zenkerene, elisapterosin, and strychnine. In recent years, his group has focused on the development of effective catalysts for highly enantioselective reactions and on the use of hydrogen bonding for catalysis of reactions. His work has been recognized through awards from Eli Lilly (1993-1995), American Cyanamid (1994), Merck (1995), and Pfizer Research Laboratories (1995-1998). He is also the recipient of the American Cancer Society Junior Faculty Award (1990-1993) and the American Chemical Society's Arthur C. Cope Scholar Award (2003).
|
|
